ION expands ETF trading capabilities with Tradeweb integration
DUBLIN - Investment manager Kevin Kotler has disclosed a 1.86% stake in Avadel Pharmaceuticals Plc, according to a regulatory filing published Wednesday.
The disclosure, made under Irish Takeover Panel rules, shows Kotler holds interests in 1,825,400 shares of the pharmaceutical company, representing approximately 1.86% of its outstanding securities.
The position includes 946,000 ordinary shares directly owned or controlled, equivalent to about 0.97% of the company, and stock-settled derivatives including options for 879,400 shares, representing roughly 0.90%.
According to the filing, Kotler sold 250,000 ordinary shares on November 18 at a price of $23.05 per share. The disclosure also details call options held by Kotler, including 4,400 shares with an exercise price of $7.50 and 875,000 shares with an exercise price of $10.00, both expiring on January 16, 2026.
The disclosure was made in compliance with Rule 8.3 of the Irish Takeover Panel Act, which requires persons with interests in relevant securities representing 1% or more to disclose their positions.
Avadel Pharmaceuticals, headquartered in Dublin, Ireland, develops pharmaceutical products focused on central nervous system conditions. The company's shares are publicly traded.
The information was disclosed in a Form 8.3 filing with the Irish Takeover Panel, which requires such disclosures when a company may be involved in a potential takeover situation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.